William Blair Brokers Decrease Earnings Estimates for IQVIA

IQVIA Holdings Inc. (NYSE:IQV) – Equities research analysts at William Blair reduced their Q1 2025 earnings per share estimates for shares of IQVIA in a research report issued on Thursday, February 6th. William Blair analyst M. Smock now anticipates that the medical research company will earn $2.35 per share for the quarter, down from their previous estimate of $2.37. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for IQVIA’s current full-year earnings is $10.81 per share.

Other equities analysts have also recently issued reports about the stock. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Redburn Atlantic started coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Monday. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $252.50.

IQVIA Trading Down 0.7 %

NYSE IQV opened at $206.67 on Monday. The firm has a market cap of $37.51 billion, a PE ratio of 27.56, a P/E/G ratio of 2.25 and a beta of 1.48. IQVIA has a one year low of $187.62 and a one year high of $261.73. The firm’s fifty day moving average is $200.67 and its two-hundred day moving average is $219.27. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%.

Insider Transactions at IQVIA

In related news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $27,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at $33,000. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the period. Finally, UMB Bank n.a. lifted its position in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 99 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.